Clene to Present at the Emerging Growth Conference

Rhea-AI Summary

Clene (Nasdaq: CLNN) announced management will present a corporate update at the Emerging Growth Conference on December 10, 2025 at 4:25 p.m. ET. The presentation will be virtual and a live webcast will be available on the company Events page and through the conference portal. A replay will be posted on the Emerging Growth YouTube channel after the event. The presentation covers company developments related to Clene's clinical-stage programs in neurodegenerative diseases including ALS and MS.

Key Figures

Conference date December 10, 2025 Virtual Emerging Growth Conference presentation

Presentation time 4:25 p.m. ET Scheduled corporate update slot at conference

Market Reality Check

$6.88 Last Close

Volume Volume 273,442 is modestly below 20-day average 313,153 (relative volume 0.87x). normal

Technical Price $5.86 is trading above 200-day MA $5.22, after a 1.56% daily gain.

Peers on Argus 1 Down

Peers show mixed moves: ATPC up 7.14%, while BRLS, PAVS, LSF, and FARM are down, with PAVS the weakest at -22.63%. This pattern points to stock-specific dynamics for CLNN rather than a broad sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 03	ALS biomarker data	Positive	-22.0%	Statistically significant ALS biomarker results supporting accelerated approval pathway.
Dec 02	Program update call	Neutral	-3.1%	Announcement of scheduled CNM-Au8 ALS program update webcast and investor call.
Nov 20	Investor conference	Neutral	+1.3%	Participation in Benchmark one-on-one investor conference with scheduled meetings.
Nov 13	Q3 earnings	Negative	-22.4%	Q3 2025 results with limited revenue, losses, and going-concern language.
Oct 20	Conference appearance	Neutral	-4.0%	Corporate update presentation at prior Emerging Growth Conference.

Pattern Detected

Recent history shows sharp selloffs around materially positive ALS data and earnings with going-concern language, while routine conference and update announcements have produced small, mixed reactions.

Recent Company History

Over the last few months, Clene has combined clinical progress with financing and visibility efforts. On Nov 13, 2025, Q3 results and going‑concern language coincided with a -22.42% move. Subsequent ALS biomarker data on Dec 3, 2025 showed statistically significant survival-linked signals but was followed by a -22.03% reaction, indicating a divergence between fundamentals and trading. In contrast, prior conference and corporate update announcements, including an Emerging Growth Conference appearance on Oct 23, 2025, saw relatively modest price changes.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-09-05

The company has an active S-3 shelf filed on 2025-09-05, with reported usage via 424B5 prospectus supplements on 2025-09-05 and 2025-10-17, indicating an established mechanism to issue additional securities if needed. Specific shelf size is not provided here.

Market Pulse Summary

The stock moved +6.3% in the session following this news. A strong positive reaction aligns with the stock’s position above its 200-day MA at $5.22 and a pre-news price of $5.86, suggesting investors sometimes reward increased visibility events such as this conference update. However, past trading showed sharp declines of -22.42% and -22.03% around material Q3 and ALS data, indicating sentiment can reverse quickly, especially with an active S-3 shelf and recent equity distribution usage documented in filings.

Key Terms

clinical-stage biopharmaceutical medical

"a clinical-stage biopharmaceutical company focused on improving mitochondrial health"

A clinical-stage biopharmaceutical is a company that is developing medicines or biological treatments that are currently being tested in people in clinical trials to assess safety and effectiveness. For investors it signals a higher-risk, higher-reward profile: progress through human testing and regulatory milestones can sharply increase value if results are positive, while failed trials can wipe out expected future revenue — like a prototype that must prove it works before it can be sold widely.

mitochondrial health medical

"company focused on improving mitochondrial health and protecting neuronal function"

Mitochondrial health describes how well the tiny energy-producing parts of cells — often called cellular “batteries” — are functioning, including their ability to make energy, manage waste, and avoid damage. It matters to investors because therapies, diagnostics, or supplements aimed at improving mitochondrial health can affect treatment options for aging, metabolic and neurodegenerative diseases, influencing clinical trial prospects, regulatory paths, and potential market size much like a new engine technology can change demand in an industry.

neuronal function medical

"improving mitochondrial health and protecting neuronal function to treat"

Neuronal function describes how brain and nerve cells send, receive and process electrical and chemical signals to control thoughts, movement, sensation and automatic body tasks. Investors care because changes in these processes are the target for many drugs and medical devices; improvements or defects can determine whether a treatment works, how safe it is, and therefore its potential market value—think of neurons as a phone network where clear connections enable reliable service.

neurodegenerative diseases medical

"protecting neuronal function to treat neurodegenerative diseases, including"

Neurodegenerative diseases are conditions where brain or nerve cells progressively lose function and die, causing symptoms like memory loss, movement problems, or cognitive decline — think of the brain’s wiring slowly wearing out. Investors care because these illnesses create sustained demand for treatments, diagnostics, and long-term care, drive regulatory decisions and clinical-trial milestones that move stock prices, and concentrate both high development risk and the potential for large financial returns if effective therapies are approved.

amyotrophic lateral sclerosis (ALS) medical

"neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and"

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that damages nerve cells responsible for controlling voluntary muscles, leading to muscle weakness, loss of movement, and eventually paralysis. It matters to investors because health-related research, treatments, and biotech companies working on ALS can influence stock markets and create opportunities or risks within the healthcare sector.

multiple sclerosis (MS) medical

"including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)"

Multiple sclerosis (MS) is a chronic neurological disease in which the immune system damages the insulating sheath around nerve fibers in the brain and spinal cord, interrupting electrical signals and causing symptoms like weakness, numbness, vision problems, and fatigue. Investors pay attention because MS drives long-term demand for therapies, clinical trial outcomes and regulatory approvals can sharply change a drugmaker’s revenue prospects, and advances or setbacks in treatment options affect long-term healthcare costs and company valuations.

virtual presentation technical

"Virtual Presentation DetailsDate: December 10, 2025Time of Presentation:"

A virtual presentation is an online live or recorded talk where a company shares financial updates, strategy, product information or guidance with investors, analysts and the public. Like a televised news segment or a video meeting, it lets more people attend easily and often includes slides and a question period, so investors watch for new facts or tone that can change expectations about a company’s future performance.

webcast technical

"A webcast of the presentation will be available on the “Events” section"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.

Virtual Presentation Details
Date: December 10, 2025
Time of Presentation: 4:25 p.m. ET
Format: Corporate update

A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register for and view the webcast here: https://goto.webcasts.com/starthere.jsp?ei=1717093&tp_key=e9cb5d164a&sti=clnn. A replay of the presentation will also be available through the conference portal and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference, following the event.

About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8^® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8^® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.

Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856

FAQ

When will Clene (CLNN) present at the Emerging Growth Conference?

Clene will present a corporate update on December 10, 2025 at 4:25 p.m. ET.

How can investors watch the Clene (CLNN) Emerging Growth Conference presentation?

Investors can watch the live webcast via the Clene Events page or register through the conference webcast link provided by the company.

Will a replay of the Clene (CLNN) presentation be available after December 10, 2025?

Yes. A replay will be available through the conference portal and on the Emerging Growth YouTube channel after the event.

What topics will Clene (CLNN) cover in the December 10, 2025 presentation?

The presentation is described as a corporate update covering company developments and clinical-stage programs focused on mitochondrial health for neurodegenerative diseases.

Where is the Clene (CLNN) webcast registration link for the Emerging Growth Conference?

The company provided a registration and webcast link in its announcement and will host the live webcast on its Events page.